Among patients with IPF, antifibrotic dose reductions and discontinuations were common, likely due to poor drug tolerability, and disease progression occurred in a substantial proportion of patients in both cohorts, regardless of antifibrotic dosing strategy, highlighting the ongoing need for more effective and better-tolerated IPF therapies.
Abstract
Background
Antifibrotic therapies nintedanib and pirfenidone slow lung function decline in patients with idiopathic pulmonary fibrosis (IPF). However, both medications are often poorly tolerated, leading to dose reductions and discontinuations in practice.
RESEARCH QUESTION
How do antifibrotic dose changes (reductions or cessations) affect disease progression in IPF?
STUDY
Design
AND
Methods
This retrospective study analyzed data for patients with IPF who initiated antifibrotic therapy using two US data sources: the multicenter Pulmonary Fibrosis Foundation Patient Registry (Registry) and Duke University Health System electronic health records (EHR). Antifibrotic dose groups were defined as full dose, reduced dose for ≥3 months, or stopped therapy for ≥3 months. Associations between antifibrotic dose group, a time-varying exposure, and IPF progression, defined as composite ≥10% decline in ppFVC, all-cause hospitalization, lung transplant, or death, were analyzed by Cox proportional-hazards models adjusted for demographics and lung function.
Results
Over a median (25th/75th percentile) follow-up of 30.0 (17.5/30.0) months in the Registry and 14.0 (7.4/29.6) months in the EHR, 347/545 (63.7%) and 609/1,027 (59.3%) patients remained on full dose, respectively. Event rates for progression per 100 person-years in patients on full dose, reduced dose, or discontinuation were 39.74, 46.62, and 70.69, respectively, in the Registry and 44.82, 40.46, and 41.72 in the EHR. Time to progression did not differ significantly between patients who reduced or stopped antifibrotics and those who remained on full dose in the Registry (HR 1.17 [95% CI 0.90-1.52] for dose reduction, 1.51 [1.04-2.18] for discontinuation; P=.073) and EHR (HR 0.87 [0.69-1.09], 0.94 [0.66-1.36]; P=.476), respectively.
Interpretation
Among patients with IPF, antifibrotic dose reductions and discontinuations were common, likely due to poor drug tolerability. Disease progression occurred in a substantial proportion of patients in both cohorts, regardless of antifibrotic dosing strategy, highlighting the ongoing need for more effective and better-tolerated IPF therapies.
INTRODUCTION
While efficacy of antifibrotics (pirfenidone and nintedanib) in idiopathic pulmonary fibrosis (IPF) is well established, its effects on combined pulmonary fibrosis and emphysema (CPFE) remain unclear. We evaluated the therapeutic efficacy of antifibrotics in CPFE patients.
METHODS
This multicentre study...
H. Gwon, Jongmin Lee, Man Pyo Chung et al.· Archivos de Bronconeumologia· 1 citation
Background/Objectives: Idiopathic pulmonary fibrosis (IPF) may progress despite antifibrotic therapy, highlighting the need for biomarkers of early treatment-associated biological changes. This study aimed to assess the potential role of hepcidin in monitoring treatment response by evaluating pre- and post-treatment se...
Gulcin Yilmaz Gunes, Hikmet Çoban, F. Erel et al.· Journal of Clinical Medicine· 0 citations
Background/Aim: Nintedanib, an antifibrotic drug, is expected to slow the progression of interstitial lung diseases (ILDs). This study aimed to evaluate the usefulness of nintedanib for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) who would otherwise be excluded due to bein...
K. Miyazaki, S. Sato, Takahide Kodama et al.· In Vivo· 0 citations
Disease-modifying therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) improve clinical outcomes, yet older patients are undertreated. In this analysis, we evaluated survival and cardiovascular-related hospitalizations (CVH) among patients treated with tafamidis (tafamidis free acid at 61 mg or bioequivalent ta...
C. Fumagalli, F. Cappelli, M. Maurer et al.· Cardiology and Therapy· 0 citations
This trial estimates the rates of adverse events, mortality, low disease activity, PPF, decline in FVC in RA-ILD, and decline in serum KL-6 in patients treated with tofacitinib NCT05246293.
J. Rojas-Serrano, E. Ramos-Martínez, M. Mejía et al.· Respiratory Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.